Paradromics Begins Human Trials of Its Neural Implant: The Challenge to Neuralink Starts

Paradromics, a neurotechnology company based in Austin, has announced that it has implanted its brain-computer interface device, Connexus, in the first participant of its clinical study approved by the U.S. Food and Drug Administration (FDA). The procedure marks a significant milestone for the company, which positions itself as a major competitor to Neuralink in the field of advanced neural technologies.

The first patient involved in the study is a woman from Michigan suffering from a motor neuron disease that has progressively compromised her ability to speak clearly. The operation was performed at the University of Michigan Health, and the protocol includes monitoring the patient for a period of six years.

According to the founder and CEO of Paradromics, Matt Angle, the ability to communicate is a fundamental aspect for people living with severe motor impairments, as it is closely linked to personal autonomy, identity, and social relationships.

Further Details on the Connexus System, Neuralink’s Rival

The Connexus system is not meant to repair the body or cure the disease. Instead, it operates by recording the neural activity generated when the patient attempts to speak. The signals collected are processed by software that converts them into text or synthesized speech displayed through a computer.

Technically, the device consists of a coin-sized implant placed on the brain's surface. Inside it are 421 microelectrodes made of platinum and iridium, each thinner than half of a human hair. The collected data is transmitted to a transceiver implanted in the chest, which communicates wirelessly through the skin.

Paradromics claims that Connexus is capable of achieving one of the highest data acquisition speeds in the industry. This is the company's first permanent implant intended to remain in the patient's body. However, the company emphasizes that this is still an early phase of experimentation. Concrete results will require months or years of observation.